Macrogenics INC 8-K filings

MacroGenics reports positive interim Phase 1 results for MGC026, an antibody-drug conjugate, with enrollment advancing in multiple cancer types.

MacroGenics, Inc. announced the resignation of Dr. Karen Ferrante from its Board of Directors, effective September 1, 2026, due to personal reasons.

MacroGenics has completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million, aiming to streamline operations and focus on its core biopharmaceutical development.

MacroGenics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals, including auditor ratification and equity plan amendments, received stockholder approval.

MacroGenics announced first quarter 2026 financial results, highlighting a strategic divestiture of manufacturing operations and expanded ZYNYZ royalty monetization, extending cash runway through 2028.

MacroGenics announced the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million upfront, aiming to streamline its focus on pipeline advancement.

MacroGenics has amended its royalty purchase agreement with Sagard Healthcare Partners, receiving an additional $60 million in cash and potential future milestone payments for its ZYNYZ royalties.

MacroGenics announces the FDA has removed a partial clinical hold on its Phase 2 LINNET study for lorigerlimab in gynecologic cancers, allowing for new patient enrollment.

Dr. Jay Siegel will not seek re-election as a Class I director at MacroGenics' 2026 Annual Meeting of Stockholders due to personal reasons.

MacroGenics announced a partial clinical hold by the FDA on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers following recent safety events.

MacroGenics announces the mutual agreement for Dr. Stephen Eck, Chief Medical Officer, to depart the company effective December 31, 2025.

MacroGenics announced its third-quarter 2025 financial results, securing $75 million in new partnership payments and extending its cash runway into late 2027, despite discontinuing a prostate cancer program.

MacroGenics reports improved Q2 2025 financial results, a new CEO, and extended cash runway through mid-2027, driven by strategic asset monetization and operational efficiency.

MacroGenics, a biopharmaceutical company, has appointed Eric Risser as its new President and Chief Executive Officer, succeeding Scott Koenig.

MacroGenics, Inc. has sold its right to receive a capped portion of future royalties on global net sales of ZYNYZ to Sagard Healthcare Partners for $70 million, extending its cash runway through the first half of 2027.

MacroGenics, Inc. held its 2025 Annual Meeting of Stockholders on May 21, 2025, where stockholders voted on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.

MacroGenics reports first patient dosed in LINNET Phase 2 study, provides clinical update expectations for LORIKEET, and advances its ADC product candidate portfolio while maintaining a cash balance of $154.1 million.

MacroGenics provides a corporate update, highlighting clinical trial advancements, pipeline prioritization, and financial results for the year ended December 31, 2024, with a focus on strategic program development and cash runway extension.

MacroGenics has amended its separation agreement with CEO Scott Koenig, extending his departure date while the board continues its search for a successor.

MacroGenics, Inc. has announced the retirement of Lynn Cilinski as Vice President, Controller, Treasurer, and Principal Accounting Officer, effective January 2, 2025, and the appointment of Beth Smith as her successor.

MacroGenics announced positive financial results for the third quarter of 2024, highlighted by a significant milestone payment and progress in its clinical pipeline.

MacroGenics announces that its President and CEO, Scott Koenig, will step down in early 2025, with a search for a new CEO underway.

MacroGenics reported updated efficacy and safety data from its Phase 2 TAMARACK trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer, showing encouraging anti-tumor activity and improved tolerability.

MacroGenics reported its second quarter 2024 financial results, highlighted by a $100 million milestone payment and progress in its clinical programs, while confirming its cash runway into 2026.

MacroGenics will present updated clinical data from its Phase 2 TAMARACK trial of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer at the ESMO Congress in September.

MacroGenics has achieved a $100 million milestone payment from Incyte related to the development of ZYNYZ (retifanlimab), extending its cash runway into 2026.

MacroGenics successfully held its 2024 Annual Meeting of Stockholders, electing three directors, ratifying the appointment of Ernst & Young LLP, approving executive compensation, and increasing the share pool for the 2023 Equity Incentive Plan.

MacroGenics reported encouraging interim safety and efficacy data from its TAMARACK Phase 2 study of vobra duo in metastatic castration-resistant prostate cancer, alongside its first quarter 2024 financial results.

MacroGenics released interim Phase 2 data for vobramitamab duocarmazine, showing encouraging results in patients with metastatic castration-resistant prostate cancer.

MacroGenics announced early interim safety data from its Phase 2 TAMARACK study of vobramitamab duocarmazine, with plans to release further data in the coming months.